FAST NEWS: Simcere Pharma Surges After Applying for New Drug Clinical Trials
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) said on Thursday its self-developed anti-tumor drug candidates SIM0237 and SIM0348 were accepted by the Center For Drug Evaluation of China’s National Medical…
FAST NEWS: Simcere Pharmaceutical Grants Overseas Rights for Drug Candidate
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Thursday that it granted Almirall S.A. exclusive rights to develop and commercialize its autoimmune drug candidate SIM0278 outside of Greater China. Looking up: Simcere…
FAST NEWS: Investment Loss Undermines Simcere Pharma’s Profit
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) on Wednesday reported its revenue grew 27.3% to 2.7 billion yuan ($389 million) in the first half of the year, while its net profit…
FAST NEWS: Simcere Pharma Posts 94% Profit Decline Amid Investment Portfolio Impairment
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) issued a profit warning on Monday, estimating a net profit of 34 million yuan ($50 million) to 94 million yuan for the six months…
FAST NEWS: New Injectable Drug from Simcere Pharma Approved For Marketing In China
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) announced Wednesday it will market Cosela, a cyclin-dependent kinase CDK4/6 inhibitor developed by the group with G1 Therapeutics, in China after receiving conditional approval from the…
FAST NEWS: Simcere Pharma Says 2021 Profit Doubled, But Shares Fall
The latest: Simcere Pharmaceutical Group Ltd. (2096.HK) released a positive profit alert on Monday evening, estimating its net profit last year was in the range of 1.48 billion ($233 million)…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cloudbreak Pharma sets sights on Hong Kong IPO after license deal
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
- Innogen Pharma jostles for a slice of the weight-loss market
